The Big Picture
Policy momentum and a steady corporate report set a constructive tone for the cannabis sector as we head into the long weekend. Curaleaf's modest revenue growth and strong margins combined with state-level wins on hemp and medical access suggest improving fundamentals for the industry.
Markets were closed on Saturday, Feb 28, so readers should note that the last trading day was Friday, February 27 and the next open is Monday, March 2. What happened in the news over the weekend will inform trading next week, but it didn't move U.S. equities until markets reopen.
Market Highlights
Key takeaways and quick facts to scan before you dig into the details.
- Curaleaf Holdings, $CURLF, reported fourth quarter FY2025 net revenue of $333 million, up 2% year over year, with a fourth-quarter gross profit margin of 49% and full year operating cash flow of $152 million.
- New Cannabis Ventures noted sector volatility in recent years, and the Global Cannabis Stock Index dropped 10.6% in January, highlighting how bumpy the recovery has been.
- Regulatory wins: Indiana failed to pass a last-minute ban on hemp-derived THC products this year, delaying restrictions until at least next year. Separately, multiple states are advancing bills to let medical cannabis patients use products in hospitals.
- Compliance risk: Ohio regulators issued a Class II recall for cannabis gummies after individual servings missed the required THC symbol. Packaging rules in California remain under scrutiny after a new industry whitepaper called for clearer standards.
- Stocks and ETFs to watch as trading resumes, including $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY. These tickers are commonly used to track sector momentum and company-specific news.
Key Developments
Curaleaf posts steady quarter, cash flow stays healthy
Curaleaf's Q4 results showed revenue of $333 million, a 2% increase from the prior year, and a robust gross margin of 49%. The company reported full year operating cash flow of $152 million and free cash flow from continuing operations of $89 million, signaling that operating discipline is improving.
For investors, that means Curaleaf, $CURLF, is generating cash while growth remains modest. You'll want to watch margins and cash conversion next quarter to see if this is durable.
Regulatory wins at the state level ease short-term uncertainty
Indiana lawmakers failed to pass a last-minute ban on intoxicating hemp-derived products, meaning those restrictions won't take effect this year. Meanwhile, several states are advancing bills to allow medical marijuana use inside hospitals, which could expand clinical access for patients who need on-site treatment.
These policy moves matter because they reduce near-term regulatory risk and broaden addressable markets. If you're positioned in hemp or medical-focused names, these outcomes lower one immediate regulatory overhang.
Compliance and packaging remain a hot button for operators
Ohio's recall of gummies for missing THC markings underscores how operational slipups can have material consequences. California's ongoing packaging debate and a new whitepaper calling for clarity highlight that regulators are still tightening standards to protect minors and ensure consistent labeling.
That means costs for compliance could rise and you'll want to monitor recalls, audits, and packaging rule changes closely. Quality control is no longer just a back-office issue, it's a balance sheet item.
What to Watch
Heading into next week you'll want to follow these catalysts and risks so you can act quickly when markets reopen on Monday, March 2.
- State legislative calendars, especially bills that affect hemp-derived THC and hospital medical use. Those votes can create near-term winners and losers for license holders.
- Federal signals on broader drug policy and psychedelics. Comments from high-level officials about speeding access to psychedelic therapies could influence investor appetite for adjacent sectors. Are regulators moving faster than companies can adapt?
- Compliance and recalls. The Ohio gummies recall is a reminder that you need to watch product-level quality and state enforcement actions. One recall can dent revenue and margins.
- Earnings and guidance from large operators, including $CURLF. Watch margin trends and cash flow metrics for signs of sustainable profitability.
- Sector ETFs and liquid names, including $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY. Which of these will benefit from renewed policy clarity and which will face headwinds from compliance costs?
Bottom Line
- Policy momentum at the state level and a steady Curaleaf quarter are constructive signs for the sector heading into March.
- Operational risks persist, with recalls and packaging rules likely to drive short-term volatility for individual companies.
- Position selectively, and favor names showing consistent cash flow and strong compliance controls.
- Watch state legislative outcomes and federal policy commentary, since either can shift sector sentiment quickly.
FAQ
Q: How did cannabis stocks perform over the week? A: As of Friday, February 27, the sector was generally steady after a volatile stretch in 2024 and 2025, with recent upside led by policy developments and steady corporate results.
Q: Does the Indiana decision change national rules for hemp THC products? A: No, it's a state-level outcome that delays a ban in Indiana until at least next year, but it reduces near-term regulatory pressure for hemp product makers operating in that state.
Q: Should you be worried about recalls and packaging rules? A: You should monitor them closely, because recalls like the Ohio gummy action can hit revenue and margins, and stricter packaging rules may raise compliance costs.